NewAmsterdam Pharma (NASDAQ:NAMS) Reaches New 12-Month Low - Here's Why

Key Points

• NewAmsterdam Pharma shares hit a new 52-week low, trading as low as $21.08 versus a prior close of $22.36. The stock remains well below its 50-day and 200-day moving averages.
• Despite the decline, analysts maintain a generally positive view, with a consensus rating of “Moderate Buy” and an average price target of $49.73; targets range from $45 to $58, although one source has a sell rating.
• The company reported a quarterly EPS loss of $0.52, worse than the $0.48 expected, while revenue of $3.70 million exceeded estimates. Insiders have sold 271,600 shares worth about $7.8 million over the past three months.

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) reached a new 52-week low during trading on Wednesday . The stock traded as low as $21.08 and last traded at $21.16, with a volume of 1732731 shares trading hands. The stock had previously closed at $22.36.

Analyst Upgrades and Downgrades

NAMS has been the topic of several research reports. Royal Bank Of Canada decreased their price target on shares of NewAmsterdam Pharma from $51.00 to $50.00 and set an "outperform" rating on the stock in a research note on Thursday, August 6th. HC Wainwright restated a "buy" rating and issued a $52.00 target price on shares of NewAmsterdam Pharma in a research report on Tuesday, September 8th. Jefferies Financial Group restated a "buy" rating and set a $45.00 price target on shares of NewAmsterdam Pharma in a research note on Monday, July 20th. Weiss Ratings restated a "sell (d-)" rating on shares of NewAmsterdam Pharma in a report on Friday, July 17th. Finally, BMO Capital Markets initiated coverage on NewAmsterdam Pharma in a research report on Monday, July 20th. They issued an "outperform" rating and a $58.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, NewAmsterdam Pharma has an average rating of "Moderate Buy" and a consensus price target of $49.73.

NewAmsterdam Pharma Price Performance

The company has a market cap of $2.53 billion, a PE ratio of -9.80 and a beta of 0.09. The stock has a 50 day simple moving average of $28.03 and a two-hundred day simple moving average of $30.99.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.52) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.04). The business had revenue of $3.70 million during the quarter, compared to analyst estimates of $2.83 million. NewAmsterdam Pharma had a negative net margin of 3,644.21% and a negative return on equity of 34.81%. As a group, equities analysts anticipate that NewAmsterdam Pharma Company N.V. will post -1.82 EPS for the current fiscal year.

Insider Activity

In related news, insider Johannes Kastelein sold 125,000 shares of the company's stock in a transaction on Monday, August 24th. The stock was sold at an average price of $26.91, for a total transaction of $3,363,750.00. Following the transaction, the insider owned 69,302 shares of the company's stock, valued at $1,864,916.82. This represents a 64.33% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CAO Louise Kooij sold 105,000 shares of the company's stock in a transaction on Monday, July 20th. The shares were sold at an average price of $30.34, for a total value of $3,185,700.00. Following the completion of the sale, the chief accounting officer directly owned 24,353 shares in the company, valued at $738,870.02. This trade represents a 81.17% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 271,600 shares of company stock valued at $7,797,962. 12.74% of the stock is owned by insiders.

Hedge Funds Weigh In On NewAmsterdam Pharma

Several institutional investors and hedge funds have recently added to or reduced their stakes in NAMS. KBC Group NV acquired a new stake in shares of NewAmsterdam Pharma in the 1st quarter valued at $37,000. AdvisorNet Financial Inc acquired a new position in shares of NewAmsterdam Pharma during the first quarter worth $82,000. Seven Fleet Capital Management LP bought a new position in shares of NewAmsterdam Pharma in the 4th quarter valued at $140,000. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in shares of NewAmsterdam Pharma in the 4th quarter valued at $253,000. Finally, PNC Financial Services Group Inc. boosted its holdings in shares of NewAmsterdam Pharma by 147.7% during the 1st quarter. PNC Financial Services Group Inc. now owns 9,119 shares of the company's stock valued at $292,000 after acquiring an additional 5,437 shares in the last quarter. 89.89% of the stock is currently owned by institutional investors.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V. is a clinical-stage biopharmaceutical company focused on developing therapies for cardiometabolic diseases, particularly conditions involving elevated cholesterol and residual cardiovascular risk. The company's lead product candidate is obicetrapib, an oral, low-dose cholesteryl ester transfer protein (CETP) inhibitor designed to reduce low-density lipoprotein cholesterol and improve other lipid parameters.

Obicetrapib has been evaluated in several clinical studies, including the Phase 3 BROADWAY trial, for patients whose cholesterol levels remain inadequately controlled despite the use of existing lipid-lowering treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.